SCHEMBL22965941

SCHEMBL22965941

CON(C)C(=O)C(C)N(C)C(=O)OC(C)(C)C

nearest known ligand 0.33

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.33
JAK3 P52333 1/20 0.32
BTK Q06187 1/20 0.32
AAK1 Q2M2I8 2/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA7 P43166 1/20 0.31
DGAT1 O75907 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25745260 1.00 FAAH (0.33) FAAHJAK3BTKAAK1CA1
SCHEMBL8647813 1.00 FAAH (0.33) FAAHJAK3BTKAAK1CA1
SCHEMBL30414771 0.90 FAAH (0.31) FAAHJAK3BTK
SCHEMBL30414719 0.90 FAAH (0.31) FAAHJAK3BTK
SCHEMBL30414734 0.90 FAAH (0.31) FAAHJAK3BTK
SCHEMBL12201977 0.83 FAAH (0.32) FAAHJAK3BTKAAK1
SCHEMBL20061314 0.83 CA1 (0.33) FAAHJAK3BTKCA1CA2
SCHEMBL60274 0.83 FAAH (0.32) FAAHJAK3BTKAAK1
SCHEMBL18796420 0.79 CA14 (0.41) AAK1CA1CA2CA7DGAT1
SCHEMBL7021061 0.79 CA14 (0.41) AAK1CA1CA2CA7DGAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590096-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists BeOne Medicines | GmbH (CH) 2026-03-31 US disclosed
US-20240294488-A1 ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC (US) 2024-09-05 US disclosed
US-20230192642-A1 ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. 2023-06-22 US disclosed
US-20230192642-A1 ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF TERRAN BIOSCIENCES INC. 2023-06-22 US disclosed
US-20220289752-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES USED AS TLR8 AGONISTS BEONE MEDICINES I GMBH (CH) 2022-09-15 US disclosed
EP-4008720-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVE USED AS TLR8 AGONIST BeiGene, Ltd. (KY) 2022-06-08 EP disclosed
EP-4008720-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVE USED AS TLR8 AGONIST BeiGene, Ltd. (KY) 2022-06-08 EP disclosed
CN-114206872-A Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR8 agonists 百济神州有限公司 2022-03-18 CN disclosed
WO-2021023105-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVE USED AS TLR8 AGONIST 百济神州有限公司 2021-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192642-A1 ISOTOPOLOGUES SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF PYGB, NR3C2, CYP11B1 FAAH 2070/4885JAK3 2225/4885BTK 4741/4885
US-20220289752-A1 IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES USED AS TLR8 AGONISTS TLR8, TLR1, TLR7 FAAH 2437/4885JAK3 224/4885BTK 853/4885
US-20240294488-A1 ISOTOPOLOGES, SALTS, CRYSTALLINE FORMS, STEREOISOMERS, OF METHYLONE AND ETHYLONE AND METHODS OF USE THEREOF CYP11B1, PYGB, CYP11B2 FAAH 2125/4885JAK3 1614/4885BTK 4785/4885
US-12590096-B2 Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists TLR8, TLR7, TLR1 FAAH 2294/4885JAK3 1229/4885BTK 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.